These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19816072)

  • 41. Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment.
    Li M; Fan Y; Li Q; Zhang P; Yuan P; Ma F; Wang J; Luo Y; Cai R; Chen S; Li Q; Xu B
    Medicine (Baltimore); 2015 Oct; 94(43):e1928. PubMed ID: 26512619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vinorelbine in breast cancer.
    Bonneterre J; Penel N
    Expert Opin Pharmacother; 2008 Nov; 9(16):2901-10. PubMed ID: 18937621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Taxanes and anthracyclines in early breast cancer: which first?
    Wildiers H; Forceville K; Paridaens R; Joensuu H
    Lancet Oncol; 2010 Mar; 11(3):219-20. PubMed ID: 20202604
    [No Abstract]   [Full Text] [Related]  

  • 44. [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer].
    Kanaji N; Bandoh S
    Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):474-8. PubMed ID: 17644943
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient perspective on sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy in HER2-negative breast cancer patients.
    Altundag K
    J BUON; 2021; 26(3):1169. PubMed ID: 34268986
    [No Abstract]   [Full Text] [Related]  

  • 46. Vinorelbine: a horse of a different color?
    Pinedo HM; Van Groeningen CJ
    J Clin Oncol; 1994 Sep; 12(9):1745-7. PubMed ID: 8083696
    [No Abstract]   [Full Text] [Related]  

  • 47. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors.
    Gennatas S; Chamberlain F; Smrke A; Stewart J; Hayes A; Roden L; Messiou C; Kowa JY; Estival A; Chauhan D; Thway K; Fisher C; van der Graaf WTA; Jones RL; Benson C
    Oncologist; 2020 Dec; 25(12):e2013-e2016. PubMed ID: 32918789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Efficacy of TS-1 as a Late-Line Treatment for Metastatic Breast Cancer].
    Murazawa C; Kontani K; Hashimoto S; Hashimoto N; Norimura S; Ohtani M; Date M; Yokomise H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1461-1463. PubMed ID: 31530791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brio: A European Prospective Observational Study to Assess the Burden of Disease and Treatment in Metastatic Breast Cancer (Mbc) Patients Treated with Oral Vinorelbine (Nvboral) or Intravenous Vinorelbine (Ivvino).
    Barni S; Mouysset JL; Sediva M; Zamagni C; Garau I
    Value Health; 2014 Nov; 17(7):A647. PubMed ID: 27202329
    [No Abstract]   [Full Text] [Related]  

  • 50. Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000-02 phase II study.
    Antón A; Barnadas A; Florián J; Ribelles N; Lomas M; Lao J; González-Quintás A; Margelí M; Paules AB; Gayo J; Ramos M;
    Clin Transl Oncol; 2011 Apr; 13(4):281-6. PubMed ID: 21493190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results.
    Aapro M; Finek J
    Cancer Treat Rev; 2012 Apr; 38(2):120-6. PubMed ID: 21742438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer.
    Smith IE
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):82-5. PubMed ID: 10442370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. UFT plus oral folinic acid with alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Coşkun U; Kaya AO; Alkis N; Buyukberber S; Alici S; Celenkoglu G; Uncu D; Ozkan M; Sevinc A; Benekli M
    Onkologie; 2009 Oct; 32(10):562-6. PubMed ID: 19816072
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
    Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
    Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I
    Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.